Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI and Safety of Lobeglitazone, Sitagliptin, and Metformin in Healthy Adults
NCT04431687Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 5 and Area Under the Curve over the Dosing Interval at Steady State at Day 5. Started Jun 2020; status: completed.
02
Drugs
lobeglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04431687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431687.